Menu
← Oncology Approval Tracker
FDA DECISION ·
Xeloda + combination treatment
capecitabine within a combination regimen · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Part of a combination regimen for adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma without prior metastatic treatment.
LAMPGEN ANALYSIS
Why it matters
This indication specifies a HER2-defined first-line metastatic population.
What research teams should watch
Verify the HER2 result and prior treatment setting and document the HER2-directed regimen component.
PRIMARY RECORDS